Challenges and hopes for Alzheimer's disease

SA Tatulian - Drug discovery today, 2022 - Elsevier
Recent drug development efforts targeting Alzheimer's disease (AD) have failed to produce
effective disease-modifying agents for many reasons, including the substantial …

Mouse models of Alzheimer's disease

M Yokoyama, H Kobayashi, L Tatsumi… - Frontiers in Molecular …, 2022 - frontiersin.org
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss
and personality changes, eventually leading to dementia. The pathological hallmarks of AD …

Targeting CDK1 in cancer: mechanisms and implications

Q Wang, AM Bode, T Zhang - NPJ precision oncology, 2023 - nature.com
Cyclin dependent kinases (CDKs) are serine/threonine kinases that are proposed as
promising candidate targets for cancer treatment. These proteins complexed with cyclins …

Lessons learned from past cyclin-dependent kinase drug discovery efforts

Z **e, S Hou, X Yang, Y Duan, J Han… - Journal of Medicinal …, 2022 - ACS Publications
Inhibition of cyclin-dependent kinases (CDKs) has become an effective therapeutic strategy
for treating various diseases, especially cancer. Over almost three decades, although great …

Network toxicological and molecular docking to investigate the mechanisms of toxicity of agricultural chemical Thiabendazole

J He, X Zhu, K Xu, Y Li, J Zhou - Chemosphere, 2024 - Elsevier
Food safety is closely linked to human health. Thiabendazole is widely used as a fungicide
and deodorant on agricultural products like vegetables and fruits to prevent fungal infections …

Small molecule '4ab'induced autophagy and endoplasmic reticulum stress-mediated death of aggressive cancer cells grown under adherent and floating conditions

SU Khan, K Fatima, U Singh, PP Singh, F Malik - Medical Oncology, 2023 - Springer
Metastasis is the leading cause of death in cancer patients and a major challenging aspect
of cancer biology. Various adaptive molecular signaling pathways play a crucial role in …

From structure modification to drug launch: A systematic review of the ongoing development of cyclin-dependent kinase inhibitors for multiple cancer therapy

Z Shi, L Tian, T Qiang, J Li, Y **ng, X Ren… - Journal of medicinal …, 2022 - ACS Publications
Herein, we discuss more than 50 cyclin-dependent kinase (CDK) inhibitors that have been
approved or have undergone clinical trials and their therapeutic application in multiple …

Triaging between post-translational modification of cell cycle regulators and their therapeutics in neurodegenerative diseases

N Rani, M Sahu, RK Ambasta, P Kumar - Ageing Research Reviews, 2024 - Elsevier
Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and
Huntington's disease, present challenges in healthcare because of their complicated …

Neuronal cell death mechanisms in Alzheimer's disease: An insight

P Goel, S Chakrabarti, K Goel, K Bhutani… - Frontiers in molecular …, 2022 - frontiersin.org
Regulated cell death (RCD) is an ordered and tightly orchestrated set of changes/signaling
events in both gene expression and protein activity and is responsible for normal …

[HTML][HTML] Inhibition of CDK4/6 regulates AD pathology, neuroinflammation and cognitive function through DYRK1A/STAT3 signaling

H Lee, HS Hoe - Pharmacological Research, 2023 - Elsevier
Repurposing approved drugs is an emerging therapeutic development strategy for
Alzheimer's disease (AD). The CDK4/6 inhibitor abemaciclib mesylate is an FDA-approved …